Network pharmacology unveiled interactions between HH and 153 NAFLD-related targets, highlighting HH’s potential to alleviate NAFLD through NF-κB signaling pathway. This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.